Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical development of kinase inhibitors not only significantly improves clinical outcomes but also facilitates the discovery of other novel driv...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Medical Oncology 2020-01, Vol.12, p.1758835919895756-1758835919895756
Main Author: Chu, Quincy S.
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
AKT protein
Epidermal growth factor
Epidermal growth factor receptors
ErbB-2 protein
Fibroblast growth factor receptor 1
Gene amplification
K-Ras protein
Kinases
Lung cancer
Lymphoma
Mutation
Neuregulin
Neuregulin 1
Non-small cell lung carcinoma
Protein-tyrosine kinase
Review
Small cell lung carcinoma
TOR protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c594t-52223bfe22a8c97057a7f2220701c79662282db880e1cebe7de1a9b81fb238bb3
cites cdi_FETCH-LOGICAL-c594t-52223bfe22a8c97057a7f2220701c79662282db880e1cebe7de1a9b81fb238bb3
container_end_page 1758835919895756
container_issue
container_start_page 1758835919895756
container_title Therapeutic Advances in Medical Oncology
container_volume 12
creator Chu, Quincy S.
description The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical development of kinase inhibitors not only significantly improves clinical outcomes but also facilitates the discovery of other novel driver mutations in non-small cell lung cancer. These driver mutations can be categorized into mutations in or near the kinase domain, gene amplification or fusion. In this review, BRAF V600E, EGFR and HER-2 exon 20 mutation, FGFR1–4, K-RAS, MET, neuregulin-1, NRTK, PI3K/AKT/mTOR, RET and ROS1 gene aberration and their therapeutics will be discussed.
doi_str_mv 10.1177/1758835919895756
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_21ad780eca1e4bbe8357ec5c06f42b44</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1758835919895756</sage_id><doaj_id>oai_doaj_org_article_21ad780eca1e4bbe8357ec5c06f42b44</doaj_id><sourcerecordid>2429461888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c594t-52223bfe22a8c97057a7f2220701c79662282db880e1cebe7de1a9b81fb238bb3</originalsourceid><addsrcrecordid>eNp1ks1v1DAQxSMEomXhzglZ4sIlYDt27HBAqio-KlXiUs7W2JlksyT2YidFe-4_Xi9byrYSF9t6fvPzePSK4jWj7xlT6gNTUutKNqzRjVSyflKc7qVyrz09Op8UL1LaUFrXoqbPi5OKU6FkJU-LmyuIPc6D74kPvkwTjCNxmJdxyZoD7zB-JG0crjGSaZlhHoInFnfBtwS3Q4sx15A-ht_zmnTg5nDkg2wCD9sR0jw4Mu6m7TpMQH4OHhKSbknZ9bJ41sGY8NXdvip-fPl8df6tvPz-9eL87LJ0shFzKTnnle2Qc9CuUVQqUF3WqKLMqaauOde8tVpTZA4tqhYZNFazzvJKW1utiosDtw2wMds4TBB3JsBg_ggh9gZibnNEwxm0KoMcMBTWYh6iQicdrTvBrRCZ9enA2i52wtahnyOMD6APb_ywNn24NnWjc3mVAe_uADH8WjDNZhrSfvDgMSzJ8EoKVvNKNNn69pF1E5bo86gMF7wRNdM5BauCHlwuhpQidvfNMGr2aTGP05JL3hx_4r7gbzyyoTwYEvT479X_Am8B1ofKTQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2429461888</pqid></control><display><type>article</type><title>Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>SAGE Journals Open Access</source><creator>Chu, Quincy S.</creator><creatorcontrib>Chu, Quincy S.</creatorcontrib><description>The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical development of kinase inhibitors not only significantly improves clinical outcomes but also facilitates the discovery of other novel driver mutations in non-small cell lung cancer. These driver mutations can be categorized into mutations in or near the kinase domain, gene amplification or fusion. In this review, BRAF V600E, EGFR and HER-2 exon 20 mutation, FGFR1–4, K-RAS, MET, neuregulin-1, NRTK, PI3K/AKT/mTOR, RET and ROS1 gene aberration and their therapeutics will be discussed.</description><identifier>ISSN: 1758-8359</identifier><identifier>ISSN: 1758-8340</identifier><identifier>EISSN: 1758-8359</identifier><identifier>DOI: 10.1177/1758835919895756</identifier><identifier>PMID: 32047535</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>1-Phosphatidylinositol 3-kinase ; AKT protein ; Epidermal growth factor ; Epidermal growth factor receptors ; ErbB-2 protein ; Fibroblast growth factor receptor 1 ; Gene amplification ; K-Ras protein ; Kinases ; Lung cancer ; Lymphoma ; Mutation ; Neuregulin ; Neuregulin 1 ; Non-small cell lung carcinoma ; Protein-tyrosine kinase ; Review ; Small cell lung carcinoma ; TOR protein</subject><ispartof>Therapeutic Advances in Medical Oncology, 2020-01, Vol.12, p.1758835919895756-1758835919895756</ispartof><rights>The Author(s), 2020</rights><rights>The Author(s), 2020.</rights><rights>The Author(s), 2020. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s), 2020 2020 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c594t-52223bfe22a8c97057a7f2220701c79662282db880e1cebe7de1a9b81fb238bb3</citedby><cites>FETCH-LOGICAL-c594t-52223bfe22a8c97057a7f2220701c79662282db880e1cebe7de1a9b81fb238bb3</cites><orcidid>0000-0003-4814-3126</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984433/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2429461888?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,313,314,723,776,780,788,881,21945,25731,27830,27899,27901,27902,36989,36990,44566,44921,45309,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32047535$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chu, Quincy S.</creatorcontrib><title>Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion</title><title>Therapeutic Advances in Medical Oncology</title><addtitle>Ther Adv Med Oncol</addtitle><description>The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical development of kinase inhibitors not only significantly improves clinical outcomes but also facilitates the discovery of other novel driver mutations in non-small cell lung cancer. These driver mutations can be categorized into mutations in or near the kinase domain, gene amplification or fusion. In this review, BRAF V600E, EGFR and HER-2 exon 20 mutation, FGFR1–4, K-RAS, MET, neuregulin-1, NRTK, PI3K/AKT/mTOR, RET and ROS1 gene aberration and their therapeutics will be discussed.</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>AKT protein</subject><subject>Epidermal growth factor</subject><subject>Epidermal growth factor receptors</subject><subject>ErbB-2 protein</subject><subject>Fibroblast growth factor receptor 1</subject><subject>Gene amplification</subject><subject>K-Ras protein</subject><subject>Kinases</subject><subject>Lung cancer</subject><subject>Lymphoma</subject><subject>Mutation</subject><subject>Neuregulin</subject><subject>Neuregulin 1</subject><subject>Non-small cell lung carcinoma</subject><subject>Protein-tyrosine kinase</subject><subject>Review</subject><subject>Small cell lung carcinoma</subject><subject>TOR protein</subject><issn>1758-8359</issn><issn>1758-8340</issn><issn>1758-8359</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1ks1v1DAQxSMEomXhzglZ4sIlYDt27HBAqio-KlXiUs7W2JlksyT2YidFe-4_Xi9byrYSF9t6fvPzePSK4jWj7xlT6gNTUutKNqzRjVSyflKc7qVyrz09Op8UL1LaUFrXoqbPi5OKU6FkJU-LmyuIPc6D74kPvkwTjCNxmJdxyZoD7zB-JG0crjGSaZlhHoInFnfBtwS3Q4sx15A-ht_zmnTg5nDkg2wCD9sR0jw4Mu6m7TpMQH4OHhKSbknZ9bJ41sGY8NXdvip-fPl8df6tvPz-9eL87LJ0shFzKTnnle2Qc9CuUVQqUF3WqKLMqaauOde8tVpTZA4tqhYZNFazzvJKW1utiosDtw2wMds4TBB3JsBg_ggh9gZibnNEwxm0KoMcMBTWYh6iQicdrTvBrRCZ9enA2i52wtahnyOMD6APb_ywNn24NnWjc3mVAe_uADH8WjDNZhrSfvDgMSzJ8EoKVvNKNNn69pF1E5bo86gMF7wRNdM5BauCHlwuhpQidvfNMGr2aTGP05JL3hx_4r7gbzyyoTwYEvT479X_Am8B1ofKTQ</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Chu, Quincy S.</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><general>SAGE Publishing</general><scope>AFRWT</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4814-3126</orcidid></search><sort><creationdate>20200101</creationdate><title>Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion</title><author>Chu, Quincy S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c594t-52223bfe22a8c97057a7f2220701c79662282db880e1cebe7de1a9b81fb238bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>AKT protein</topic><topic>Epidermal growth factor</topic><topic>Epidermal growth factor receptors</topic><topic>ErbB-2 protein</topic><topic>Fibroblast growth factor receptor 1</topic><topic>Gene amplification</topic><topic>K-Ras protein</topic><topic>Kinases</topic><topic>Lung cancer</topic><topic>Lymphoma</topic><topic>Mutation</topic><topic>Neuregulin</topic><topic>Neuregulin 1</topic><topic>Non-small cell lung carcinoma</topic><topic>Protein-tyrosine kinase</topic><topic>Review</topic><topic>Small cell lung carcinoma</topic><topic>TOR protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chu, Quincy S.</creatorcontrib><collection>SAGE Journals Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Therapeutic Advances in Medical Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chu, Quincy S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion</atitle><jtitle>Therapeutic Advances in Medical Oncology</jtitle><addtitle>Ther Adv Med Oncol</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>12</volume><spage>1758835919895756</spage><epage>1758835919895756</epage><pages>1758835919895756-1758835919895756</pages><issn>1758-8359</issn><issn>1758-8340</issn><eissn>1758-8359</eissn><abstract>The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical development of kinase inhibitors not only significantly improves clinical outcomes but also facilitates the discovery of other novel driver mutations in non-small cell lung cancer. These driver mutations can be categorized into mutations in or near the kinase domain, gene amplification or fusion. In this review, BRAF V600E, EGFR and HER-2 exon 20 mutation, FGFR1–4, K-RAS, MET, neuregulin-1, NRTK, PI3K/AKT/mTOR, RET and ROS1 gene aberration and their therapeutics will be discussed.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>32047535</pmid><doi>10.1177/1758835919895756</doi><orcidid>https://orcid.org/0000-0003-4814-3126</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1758-8359
ispartof Therapeutic Advances in Medical Oncology, 2020-01, Vol.12, p.1758835919895756-1758835919895756
issn 1758-8359
1758-8340
1758-8359
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_21ad780eca1e4bbe8357ec5c06f42b44
source Open Access: PubMed Central; Publicly Available Content Database; SAGE Journals Open Access
subjects 1-Phosphatidylinositol 3-kinase
AKT protein
Epidermal growth factor
Epidermal growth factor receptors
ErbB-2 protein
Fibroblast growth factor receptor 1
Gene amplification
K-Ras protein
Kinases
Lung cancer
Lymphoma
Mutation
Neuregulin
Neuregulin 1
Non-small cell lung carcinoma
Protein-tyrosine kinase
Review
Small cell lung carcinoma
TOR protein
title Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T09%3A28%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20non-small%20cell%20lung%20cancer:%20driver%20mutation%20beyond%20epidermal%20growth%20factor%20mutation%20and%20anaplastic%20lymphoma%20kinase%20fusion&rft.jtitle=Therapeutic%20Advances%20in%20Medical%20Oncology&rft.au=Chu,%20Quincy%20S.&rft.date=2020-01-01&rft.volume=12&rft.spage=1758835919895756&rft.epage=1758835919895756&rft.pages=1758835919895756-1758835919895756&rft.issn=1758-8359&rft.eissn=1758-8359&rft_id=info:doi/10.1177/1758835919895756&rft_dat=%3Cproquest_doaj_%3E2429461888%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c594t-52223bfe22a8c97057a7f2220701c79662282db880e1cebe7de1a9b81fb238bb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2429461888&rft_id=info:pmid/32047535&rft_sage_id=10.1177_1758835919895756&rfr_iscdi=true